Kornimate/medical-research-clean huggingface dataset:
nutrition thinking® trial

Conditions: Overweight

Summary: the purpose of this study is to scientifically validate nutrition thinking®, a novel nutritional approach based on the values and methodologies of design thinking.

the concept of nutrition has changed exponentially in recent decades to include a range of challenges that were not foreseen. the strength of this movement is based on the understanding of (1) the complexity with which people face their nutritional challenges; and (2) the interconnection between food systems and overlapping health risks associated with malnutrition, obesity, and climate change. maintaining an adequate weight, a healthy and sustainable diet pattern are complex well-established challenges. however, current nutritional approaches to lose weight, based on functional experiences, often fail to promote long-term adherence to dietary recommendations and maintaining lost weight. the ambiguity and complexity that involves an interactional nutrition, based on the experiences involved in how people act at the individual level and their relationships with the environment and dynamic systems, brings up the challenge of designing meaningful learning experiences to promote a change of culture and positive impact. current social changes demand the search for novel nutritional approaches based on methodologies that result in meaningful experiences. we need new ways to build diets that balance the needs of individuals and society as a whole, new ideas that address global challenges, new strategies that result in differences that matter, and a sense of purpose that includes everyone involved. with that in mind, nutrition thinking® arises as a nutritional approach based on the values and methodologies of design thinking, an abstraction of a mental model for addressing complex problems and conducting projects based on empathy, collaboration, and experimentation. therefore, nutrition thinking® represents a new nutrition learning matrix based on experience for the co-creation of authentic and sustainable diets.

Eligibility criteria:
inclusion criteria: * age between 25 and 35 years old of both sexes; * nutritional diagnosis of overweight (bmi between 25-29.9 kg/m2); * available to participate in the sessions proposed by the protocol (every 15 days for a period of 3 months). exclusion criteria: * presence of characteristics that make nutritional assessment impossible (eg. presence of metallic prostheses or amputated limbs); * previous involvement in any clinical trial, nutritional or medical intervention for weight loss in the 6 months prior to recruitment; * previous history of eating disorders (anorexia, bulimia, binge eating); * presence of congenital diseases; * presence of thyroid disease, hypertension, dyslipidemia and diabetes, defined through medical diagnosis associated with drug treatment and / or previous or current cardiovascular disease; * pregnant or lactating women.

Keywords: nutrition thinking nutritional approach diet design thinking overweight
tailored worksite weight control programs

Conditions: Obesity

Summary: given the prevalence of overweight and obesity, worksite-based health promotion programs have been recommended due to their potential reach and social support impact. within worksite contexts, many strategies to prevent and treat obesity have focused on educational programs delivered in person or to small groups that target knowledge acquisition and strategies targeted at individuals to improve their dietary and activity practices. these programs have been criticized because they typically reach a small percentage of workers-and seldom those that could benefit most, are of short duration, and have typically small effects that are not sustained. they have also typically been conducted in large worksites that have the greatest resources. the lack of success of these programs may be due to: 1) inadequate intervention intensity, 2) implementation challenges, and 3) a lack of theoretical models as the bases for intervention development. to overcome the limitations of previous research we will conduct a 2 group randomized controlled trial to determine the reach and effectiveness of an extensive intervention that: (a) is based upon sound theory, (b) is delivered primarily through scalable interactive technologies, and (c) leverages the existing organizational and environmental context of the workplace.

this study will test the utility of a social ecological theory, individually-targeted internet-based intervention with monetary incentives to reduce the weight of overweight and obese employees (incent) when compared to a low-intensity, internet-based weight loss program without incentives (livin my weigh). participants in incent will receive daily e-mail support that facilitates goal setting, regular assessments of body weight, and incentives based on percent of original body weight lost at the end of each quarter over the 12-month program. the e-mail supports will target improving perceptions of self-efficacy and outcome expectations related to weight loss or maintaining a healthy weight. in addition e-mail support will facilitate participant problem solving and identification of resources for healthful eating and physical activity at home, in their neighborhoods, and at their worksite. participants in livin my weigh (lmw)will receive evidence-based physical activity and nutrition information to facilitate weight loss through quarterly newsletters and quarterly educational sessions.

Eligibility criteria:
inclusion criteria: * employed full time at an eligible worksite * access to the internet * bmi \> 25 exclusion criteria: * bmi \< 25 * no internet access

Keywords: worksite weight loss obesity
photoplethysmography (ppg) algorithm with smartwatch in evaluation of atrial fibrillation burden after catheter ablation

Conditions: Atrial Fibrillation (AF)

Summary: the purpose of this study is to evaluate the effectiveness of a smart electrocardiogram watch based on the ppg algorithm in monitoring the atrial fibrillation burden of patients after catheter ablation.


Eligibility criteria:
inclusion criteria: 1. atrial fibrillation patients diagnosed by electrocardiogram 2. received catheter ablation procedure 3. willing to use long-range electrocardiogram monitoring equipment exclusion criteria: 1.patients who are allergic to electronic devices or unable to wear watches

Keywords: atrial fibrillation burden、 catheter ablation photoplethysmography wearable devices.
a non-interventional naturalistic project to investigate the effect of the use of sms text service on treatment adherence in patients treated with seroquel® (quetiapine)

Conditions: Bipolar Disorder; Schizophrenia

Summary: the basic hypothesis of this trial is that forgetfulness and failure to establish a routine that facilitates medication adherence are prominent reasons for non-adherence. daily use of the sms text messages is designed to enhance patient adherence with medication by promoting daily routine and demonstrate the feasibility of using sms technology within normal clinical practice in the netherlands. please note: seroquel sr and seroquel xr refer to the same formulation. the sr designation was changed to xr after consultation with fda.


Eligibility criteria:
inclusion criteria: * the subjects should be considered eligible for this trail according to the physician: 1. patients with a diagnose of schizophrenia or bipolar disorder with a recent manic episode 2. patients who are being treated with quetiapine and are on an effective dose according to the core data sheet; for schizophrenia between 300 and 450 mg (maximum 750 mg) and bipolar disorder between 400 and 800 mg. 3. patients who consent to make the coded data available to astrazeneca; provision of written informed consent 4. considered eligible for this study and able to understand and comply with the requirements of the study according to the physician 5. in possession of a private mobile phone and capable of using this mobile phone to send sms text messages exclusion criteria: * subjects who, in the opinion of the physician, pose an imminent risk of suicide or a danger to themselves or others are excluded from the trial.

Keywords: patients with a manic episode or patients diagnosed with schizophrenia , patients who are being treated with quetiapine and are on a stable dosing regime
phenotypes of nonproliferative diabetic retinopathy in dm 2 patients identified by oct, cfp, rla and mferg (diamarker)

Conditions: Type-2 Diabetes; Diabetic Retinopathy

Summary: to characterise phenotypes of non proliferative diabetic retinopathy (npdr) progression using multimodal testing/imaging procedures.


Eligibility criteria:
inclusion criteria: 1. age over 18 years-old. 2. diabetes mellitus type 2 according to 1985 who criteria. 3. non-proliferative diabetic retinopathy (etdrs level \<= 35) 4. signs of npdr progression based on existing clinical information: 1. retinal thickness (rt) increase (increase in rt above normal range as measured by oct, considering the macular thickness normative data) in the central subfield, the inner ring and/or the outer ring (leaking phenotype); or 2. neovascular disease activity as shown by microaneurysms (ma) turnover (ma formation rate \>= 2, i.e. number of new ma per year) computed from cfp using the retmarkerdr software (ischemic phenotype). 5. informed consent. exclusion criteria: 1. cataract or other eye disease that may interfere with fundus examinations 2. any eye surgery or treatment within a period of 6-months. 3. pregnant or nursing (lactating) women. 4. patients with chronic or severe kidney disease (glomerular filtration rate, gfr \< 30 ml/min/1.73m2). 5. patients with acute kidney injury. 6. patients with known allergic or hypersensitivity reactions to gadolinium, versetamide or any of the inert ingredients. 7. patients around the time of liver transplantation.. 8. patients with implants containing metals.
possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine

Conditions: Ulcerative Colitis

Summary: to evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine

a randomized, controlled, and parallel study will comprise 46 patients with uc. patients will be recruited from gastroenterology department, mansoura university hospital. the participants will be randomly assigned into two groups as follow: group 1: control group (mesalamine group, n =23) who will receive 1 g mesalamine three times daily for 6 months. group 2: (mebendazole group, n = 23) which will receive the standard treatment for uc plus mebendazole 500 mg twice daily for 6 months.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old both male and female will be included mild and moderate uc patients diagnosed and confirmed by endoscope patient treated with 5-aminosalislic acid (mesalamine) exclusion criteria: * - patients with severe uc * significant liver and kidney function abnormalities * diabetic patients * patients with colorectal cancer patients * patients taking rectal or systemic steroids * patients on immunosuppressants or biological therapies * addiction to alcohol and / or drugs * known allergy to the studied medications * history of complete or partial colectomy. * patients with congestive heart failure, other heart disease (arrhythmia, ischemic heart disease including angina and myocardial infarction). * patients with other inflammatory diseases and active infection. * patients with stressful condition (copd, morbid obesity). * patients with liver disease. * patients with thrombocytopenia and neutropenia. * patients with any type of seizures (case report for mebendazole induced convulsion). * patients with renal disease (case report for mebendazole induced nephrotoxicity). * patients with coagulation disorders. * patients on metronidazole (to avoid stevens-johnson syndrome). * patients with hypersensitivity to mebendazole, albendazole or benzimidazole * patients using antioxidants. * pregnant and lactating females. * patients receiving, metronidazole, warfarin, low dose of aspirin, clopidogril, enzyme inducers (phenytoin, carbamazepine) and inhibitors (valoproate) to avoid potential pharmacodynamics and pharmacokinetic interactions.

Keywords: mbz, uc
ihero study: insurance, health and economic resources online for emerging adults with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: this research study aims to test a financial and health insurance ihero toolkit for young adults with type1 diabetes. the ihero toolkit was developed over one year with the type 1 diabetes community, the diabetes link organization, and experts. now, the investigators want to understand the impact of the ihero toolkit on diabetes self-management, financial stress, and health insurance literacy outcomes. the investigators are doing this study because it will help to better understand how to support health insurance and financial stress and improve self-management outcomes in young adults with type 1 diabetes. the investigators want to understand how the ihero toolkit helps all young adults with diabetes, but especially those on medicaid and who are racially or ethnically diverse. the investigators will ask participants to participate at four-time points over one year. for the first time, participants will fill out online enrollment and demographic forms and 9 surveys. the 9 surveys have 8-40 short questions each, estimated to take about 45 minutes. participants will also be asked to complete a home a1c collection with a university hospitals team member on zoom.


Eligibility criteria:
inclusion criteria: * age range: 18-30 years * diagnosis of type 1 diabetes (t1d) * t1d duration for one year or longer * geographical location: residing in the united states. exclusion criteria: * inability to answer questions due to cognitive status. * inability to read or understand english. * diagnosis of insulin-dependent diabetes that is not t1d such as cystic fibrosis-related diabetes, maturity-onset diabetes of the young, or insulin-dependent type 2 diabetes.

Keywords: type 1 diabetes health insurance financial stress young adults health insurance literacy
expanded access trial of plant expressed recombinant glucocerebrosidase (prgcd) in patients with gaucher disease

Conditions: Gaucher Disease

Summary: this is an open-label expanded access trial of prgcd in patients with gaucher disease who require enzyme replacement therapy (ert) and who have been treated with imiglucerase but for whom the dose has been reduced or discontinued due to shortage of the product.

gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (gcd), which have been mapped to chromosome 1 q21-q31, leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (glccer) in the cells of the monocyte-macrophage system. this accumulation leads to the visceral manifestations of hepatosplenomegaly, anemia and thrombocytopenia, as well as to the skeletal features and less frequently also to lung involvement. prgcd is a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of gaucher disease. expression of proteins in plant cell culture is highly efficient, does not require post-expression modification of the protein, and is not susceptible to contamination by agents such as viruses that are pathological to humans. prgcd safety will be observed in this treatment protocol of patients with non-neuronopathic gaucher disease who require enzyme replacement therapy. eligible patients will receive intravenous (iv) infusions of prgcd every two weeks. the dose of prgcd will be equal to each patient's previous imiglucerase dose before reduction or discontinuation due to shortage. the infusions will be administered at the selected medical center.

Eligibility criteria:
inclusion criteria: * males and females, 18 years or older * diagnosis of gaucher disease treated historically with imiglucerase * able to provide written informed consent exclusion criteria: * currently taking another experimental drug for any condition * history of allergy to carrots * previous infusion reaction suspected to be allergic in nature to cerezyme® or ceredase® or receiving premedication to prevent infusion reactions * allergy to beta-lactam antibiotics * presence of any medical, emotional, behavioral or psychological condition that in the judgment of the investigator would interfere with the patient's compliance with the requirements of the study.

Keywords: glucocerebrosidase enzyme replacement therapy gaucher disease plant cell culture splenomegaly hepatomegaly anemia thrombocytopenia
the role of fetal ductus arteriosus in predicting spontaneous labour at term

Conditions: Ductus Arteriosus

Summary: the exact mechanism stimulating the parturition in humans is still relatively unknown. prostaglandins, by mediating cervical ripening and early stimulation of myometrial contractions, are likely to play a major role in the parturition process. much of the unique fetal circulation is facilitated by the ductus arteriosus. patency of the ductus arteriosus in utero is primarily maintained via prostaglandins which are highly expressed by smooth muscle cells located in the media of the ductus arteriosus. the aim of the study is to prospectively observe fetal ultrasound changes related to the ductus arteriosus. the primary objective is to prospectively assess, whether any changes in the fetal ductus arteriosus parameters exist at 40 weeks' gestation. the secondary objective is to investigate whether there is an association between the ductus arteriosus parameters and the time to delivery interval at 40 weeks' gestation.

the rationale is to assess whether physiological responses that occur around the time of delivery, in both the mother and the fetus (elevated prostaglandins level), can be quantified using ultrasound of the fetal ductus arteriosus. whether or not the da plays an active physiological role in the initiation of parturition is still unknown. since prostaglandins are physiologically highly expressed within the fetal ductus arteriosus and also linked to some critical steps throughout parturition, it is hypothesized that structural and doppler flow pattern variations of the ductus arteriosus exist in the period surrounding the birth. these changes might occur before or after the intrinsic rise of prostaglandins and could be quantified using prenatal ultrasound of the fetal da. identifying new physiological based variables that can assist in predicting the onset of labour, as the one suggested in the current study, is thus of great importance and may provide invaluable information into the overall future care and decision making during pregnancy, especially around the time of delivery. it may assist in creating future recommendations for pregnant women and improved healthcare standards during the delivery process.

Eligibility criteria:
inclusion criteria: * low risk singleton pregnancy at 40 weeks gestation. exclusion criteria: * smoking * underlying cardiac or respiratory illness * fetal growth restriction * medicated gestational hypertension or evolving preeclampsia * gestational diabetes controlled with insulin or oral medications * use of steroids for lung maturation in the current pregnancy * known major congenital anomalies.
nutritional status in children with down syndrome

Conditions: Down Syndrome

Summary: to evaluate the nutritional status of children with down's syndrome and to determine the prevalence of nutritional deficiencies among those children. to discuss factors associated with their nutritional status, such as dietary habits and comorbid health conditions.


Eligibility criteria:
inclusion criteria: clinical diagnosis of children with down's syndrome age between 2- 5 years of both sexes exclusion criteria: children diagnosed with any other chronic illness or any other medical problem
instant and lasting relief effects of strontium chloride/potassium nitrate dentifrice on dentin hypersensitivity

Conditions: Dentine Hypersensitivity

Summary: the objective of the present study was to compare the effects of a commercially available dentifrice containing 2% strontium chloride and 5% potassium nitrate in a silica base, versus a control dentifrice, containing exactly the same ingredients apart from strontium chloride and potassium nitrate, on the instant and lasting relief of dh.

dentin hypersensitivity (dh) is a very common complaint that occurs in the general population. the intensity of the pain can be minor to very serious, which may prevent one from eating or performing ordinary oral hygiene practices. the most accepted mechanism by which dh occurs is hydrodynamic theory, which suggests that pain-producing stimuli cause rapid movement of fluid within the dentin tubules, as a result the free nerve endings, at the inner ends of the tubules or the periphery of the pulp, are excited and dh occurs. according to this theory, one approach to treat dh is reducing dentin tubule fluid movement through occluding open tubules. strontium chloride was the first tubule-blocking ingredient used in dentifrice about fifty years ago and since that time a paucity of clinical studies have been carried out to test its effectiveness on dh. the other approach is to reduce the pulp nerve excitability by depolarizing the nerve endings, in which the most widely used material is potassium salts. although there is limited clinical evidence that dentifrices containing strontium chloride or potassium nitrate alone, as the major desensitizing agent, has an effect on reducing dh, no clinical studies have shown the effectiveness of a dentifrice containing both strontium chloride and potassium nitrate in a silica base on alleviating dh.

Eligibility criteria:
inclusion criteria: * good oral and general health * possessing at least two teeth (incisors, cuspids, bicuspids and first molars with exposed cervical dentin) with hypersensitivity on facial surfaces which satisfied a tactile hypersensitivity stimulus score of 10-50 grams of force (yeaple probe) and an air blast stimulus score of 2 or 3(schiff cold air scale) * provided informed consent and were available for the study duration exclusion criteria: * progressive periodontitis, with teeth that had extensive restoration, suspected pulpitis, caries, cracked enamel or that were used as abutments for removable partial dentures, * had hypersensitive teeth with a mobility greater than one * had received periodontal treatment including surgery during the last year * had used any other anti-hypersensitivity dentifrice or taken part in any other clinical trial, used any desensitizing agents during the last three months, or allergic to the ingredients of the dentifrices were excluded * pregnant or breastfeeding women * had taken the following drugs during the last month: anticonvulsants, antihistamines, antidepressants, sedatives, tranquilizers, anti-inflammatory drugs or daily analgesics

Keywords: dentifrice potassium nitrate strontium chloride